Othman Laraki
Angel Investor
San Francisco, United States
Othman Laraki is a seed investor in San Francisco focused on Software and Information Technology. Othman Laraki is based out of San Francisco, California and is the Co-founder and CEO of Color Health. Othman previously worked at Google as a Product leader. Othman Laraki attended the Stanford University.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Othman Laraki invests in
Stages Othman Laraki invests in
Countries Othman Laraki invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $775k–$14M
- Pre-Seed
- $500k–$2M
- Series A
- $1.5M–$29M
Investment Focus
Industry
- Software 11 (24%)
- Information Technology 10 (22%)
- Internet 9 (20%)
- Health Care 8 (17%)
- Artificial Intelligence 8 (17%)
Stage
- Seed 29 (63%)
- Series A 5 (11%)
- Pre-Seed 4 (9%)
- Angel 3 (7%)
- Funding Round 2 (4%)
Country
- United States 39 (85%)
- India 1 (2%)
- France 1 (2%)
- Sweden 1 (2%)
- The Netherlands 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bravi offers an AI‑powered voice and chat assistant that handles lead qualification, appointment booking, and CRM integration. | $1.8M / Pre-Seed / Sep 15, 2026 | ||
| Uncovr is an AI-powered surgical intelligence and documentation platform that automatically transforms operating room videos into structured clinical reports and billing codes. | $7M / Seed / Jun 10, 2026 | ||
| SRE.ai delivers AI agents that automate Salesforce DevOps workflows, allowing for fast, transparent deployments, back-promotions, and impact analysis. With seamless tool integration, SRE.ai minimizes clicks and maximizes productivity, enabling teams to scale without sacrificing quality or speed. | $7.2M / Seed / Aug 20, 2025 | ||
| Bluenote Health operates as an AI platform for life sciences. | $10M / Dec 20, 2024 | ||
| Yupp a discovering, contrasting, and utilizing the newest AIs is made simple and enjoyable, which also contributes to the field's future development.. | $33M / Seed / Jun 01, 2024 | ||
| YardStream is a Metaverse company & an all-in-one virtual and hybrid event platform for virtual events, summits, meetups, workshops and in-person events for communities & enterprises. Specializing in augmented reality solutions, spatial mapping and 3D models. Each Business Delivers a Disruptive End-to-End Solution Backed by AI, 3D, AR, andML. | $500K / Pre-Seed / Dec 15, 2023 | ||
| Exponential DeFi platform makes it easy to discover, assess, and invest in DeFi yield opportunities. | $14M / Seed / Oct 03, 2022 | ||
| Evernow is a provider of women's health care services before, during, and after menopause. Their platform has online access to specialized doctors, science-backed information, and treatments, along with conversations and information about effective care for changing hormones, enabling women to live longer and healthier lives. | $28.5M / Series A / Apr 06, 2022 | ||
| Detail Technologies is a virtual camera that you can use in Zoom, Loom, Meet, Whereby, or your favorite streaming software. | $2M / Pre-Seed / Mar 09, 2021 | ||
| Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | $19.5M / Seed / Sep 17, 2018 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Othman Laraki invest in?
Othman Laraki invests primarily in Software, Information Technology and Internet startups, most often at Seed and Series A stage. Most of the 46 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Othman Laraki invest in?
Othman Laraki typically joins rounds of $775k–$14M at Seed, $500k–$2M at Pre-Seed and $1.5M–$29M at Series A. These are whole funding-round sizes, not Othman Laraki's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Othman Laraki took part in.
How do I contact Othman Laraki?
Public channels for Othman Laraki include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Othman Laraki last invest?
The most recent investment recorded for Othman Laraki closed in Sep 2026. Shizune tracks 46 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
